title: Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients.
abstract: Alterations in microRNAs (miRNAs) have been considered to have diagnostic implications in most diseases, but few studies have reported dysregulated miRNAs in schizophrenia (SCZ). In order to observe an association between miRNAs and SCZ, this study was designed to investigate expression profiling of miRNAs in peripheral blood mononuclear cells (PBMCs). miRNA microarray technology was employed to compare the expression of miRNAs in PBMCs from SCZ patients (n=105) and normal controls (n=130), and real-time quantitative polymerase chain reaction (QPCR) was used to analyze the results. Several important miRNA levels were examined before and after antipsychotic treatment in first-onset SCZ patients. In addition, an SCZ-like rat model was established using dizocilpine (MK-801), and miR-132 expression in PBMCs and whole-brain tissue from SCZ-like rats was studied using QPCR. In humans, dysregulated miRNAs were observed before treatment and QPCR verified that miR-132, miR-134, miR-1271, miR-664(⁎), miR-200c and miR-432 levels were significantly decreased (P<0.01 for all) in PBMCs of SCZ patients compared with healthy controls. After antipsychotic treatment there was a marked increase in miR-132 (P<0.01), miR-664(⁎) (P<0.05) and miR-1271 (P<0.05) levels in SCZ patients compared with the levels before treatment. In the animal assays, miR-132 levels declined in PBMCs and whole-brain tissues (both P<0.05) of the SCZ-like rats compared to controls. For the first time, our results suggest that miR-132 is a potential and superior biomarker in peripheral blood that will allow discrimination of SCZ patients from healthy controls.
authors.affiliation: School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, PR China; Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine in Henan Province, Xinxiang 453003, PR China; The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, PR China; Department of Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou 450001, PR China.
authors.forename: Hai-chuan
authors.initials: HC
authors.lastname: Yu
authors.affiliation: School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, PR China.
authors.forename: Jiao
authors.initials: J
authors.lastname: Wu
authors.affiliation: Department of Psychology, Xinxiang Medical University, Xinxiang 453003, PR China; The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, PR China.
authors.forename: Hong-xing
authors.initials: HX
authors.lastname: Zhang
authors.affiliation: School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, PR China.
authors.forename: Gao-li
authors.initials: GL
authors.lastname: Zhang
authors.affiliation: School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, PR China.
authors.forename: Juan
authors.initials: J
authors.lastname: Sui
authors.affiliation: School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, PR China.
authors.forename: Wen-wen
authors.initials: WW
authors.lastname: Tong
authors.affiliation: School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, PR China.
authors.forename: Xin-ya
authors.initials: XY
authors.lastname: Zhang
authors.affiliation: The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, PR China.
authors.forename: Li-li
authors.initials: LL
authors.lastname: Nie
authors.affiliation: School of Laboratory Medicine, Xinxiang Medical University, Xinxiang 453003, PR China.
authors.forename: Ju-hong
authors.initials: JH
authors.lastname: Duan
authors.affiliation: Department of Pharmacology, School of Medicine, Zhengzhou University, Zhengzhou 450001, PR China.
authors.forename: Li-rong
authors.initials: LR
authors.lastname: Zhang
authors.affiliation: The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang 453002, PR China. Electronic address: lvx928@126.com.
authors.forename: Lu-xian
authors.initials: LX
authors.lastname: Lv
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D005106:Exploratory Behavior / Q000187:drug effects; D005260:Female; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007398:Interpersonal Relations; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008297:Male; D035683:MicroRNAs / Q000097:blood* / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D012372:ROC Curve; D051381:Rats; D017207:Rats, Sprague-Dawley; D012189:Retrospective Studies; D012559:Schizophrenia / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D018691:Excitatory Amino Acid Antagonists; C547077:MIRN132 microRNA, human; D035683:MicroRNAs; D016291:Dizocilpine Maleate
keywords: Biomarker; Peripheral blood; Schizophrenia; miR-132; microRNA